[go: up one dir, main page]

NO991734L - Pyrazolinones for the treatment of potency disorders - Google Patents

Pyrazolinones for the treatment of potency disorders

Info

Publication number
NO991734L
NO991734L NO991734A NO991734A NO991734L NO 991734 L NO991734 L NO 991734L NO 991734 A NO991734 A NO 991734A NO 991734 A NO991734 A NO 991734A NO 991734 L NO991734 L NO 991734L
Authority
NO
Norway
Prior art keywords
treatment
pyrazolinones
potency disorders
disorders
potency
Prior art date
Application number
NO991734A
Other languages
Norwegian (no)
Other versions
NO991734D0 (en
Inventor
Michael Arlt
Rochus Jonas
Pierre Schelling
Maria Christadler
Franz-Werner Kluxen
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO991734L publication Critical patent/NO991734L/en
Publication of NO991734D0 publication Critical patent/NO991734D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Anvendelse av forbindelser med formel (I) hvor R1, R2 og R3 har de i krav l angitte betydninger, til behandling og/eller terapi av potensforstyrrel- ser.Use of compounds of formula (I) wherein R 1, R 2 and R 3 have the meanings specified in claim 1 for the treatment and / or therapy of power disorders.

NO991734A 1996-10-14 1999-04-13 Pyrazolinones for the treatment of potency disorders NO991734D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19642284A DE19642284A1 (en) 1996-10-14 1996-10-14 Pyrazolinones for the treatment of erectile dysfunction
PCT/EP1997/005532 WO1998016224A1 (en) 1996-10-14 1997-10-08 Pyrazolinones to treat disturbances of potency

Publications (2)

Publication Number Publication Date
NO991734L true NO991734L (en) 1999-04-13
NO991734D0 NO991734D0 (en) 1999-04-13

Family

ID=7808669

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991734A NO991734D0 (en) 1996-10-14 1999-04-13 Pyrazolinones for the treatment of potency disorders

Country Status (14)

Country Link
EP (1) EP0930881A1 (en)
JP (1) JP2001501958A (en)
KR (1) KR20000049086A (en)
CN (1) CN1233178A (en)
AR (1) AR008494A1 (en)
AU (1) AU4945297A (en)
BR (1) BR9712307A (en)
CA (1) CA2268823A1 (en)
DE (1) DE19642284A1 (en)
HU (1) HUP0000233A3 (en)
NO (1) NO991734D0 (en)
PL (1) PL332821A1 (en)
WO (1) WO1998016224A1 (en)
ZA (1) ZA979151B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6875575B1 (en) 1998-11-25 2005-04-05 Osi Pharmaceuticals, Inc. Diagnostic methods for neoplasia
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
WO2006034473A2 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
DE19518082A1 (en) * 1995-05-17 1996-11-21 Merck Patent Gmbh 4 (-Arylaminomethylene) -2,4-dihydropyrazol-3-one

Also Published As

Publication number Publication date
HUP0000233A2 (en) 2001-04-28
PL332821A1 (en) 1999-10-11
AR008494A1 (en) 2000-01-19
ZA979151B (en) 1998-05-11
KR20000049086A (en) 2000-07-25
CA2268823A1 (en) 1998-04-23
CN1233178A (en) 1999-10-27
WO1998016224A1 (en) 1998-04-23
HUP0000233A3 (en) 2001-06-28
JP2001501958A (en) 2001-02-13
AU4945297A (en) 1998-05-11
BR9712307A (en) 1999-08-31
EP0930881A1 (en) 1999-07-28
DE19642284A1 (en) 1998-04-16
NO991734D0 (en) 1999-04-13

Similar Documents

Publication Publication Date Title
NO992821L (en) Ketobenzamides as Calpain Inhibitors
NO20075065L (en) Use of isoflavone compounds to treat heart disease
TR199901905T2 (en) 2- (P�rin-9-yl) -tetrahidrofuran-3,4-diol t�revleri.
BG105270A (en) Tetrahydropyridoethers
NO991951L (en) Tienopyrimidines with phosphodiesterase V inhibitory effect
EA200000723A1 (en) DERIVATIVES 2- (PURIN-9-IL) -TETRAHYDROFURAN-3,4-DIOLA
HU9303515D0 (en) Pyrrolo-pyrimidines
GB9514473D0 (en) Chemical compounds
AU2291097A (en) Novel phenanthridines substituted in the 6 position
BG103399A (en) New heterocycle-substituted benzamides and their application for the treatment of diseases
DE69723863D1 (en) CHINOLINE AND THEIR THERAPEUTIC USE
IT1285770B1 (en) CORTICOID COMPOUNDS
NO991734L (en) Pyrazolinones for the treatment of potency disorders
ATE265455T1 (en) TETRAHYDROPYRIDO COMPOUNDS
ATE53377T1 (en) 1-SUBSTITUTED TETRALINE DERIVATIVES, THEIR PREPARATION AND USE.
NZ240481A (en) Aminosulphonyl urea derivatives and pharmaceutical compositions
NO20001934L (en) 3-Substituted tetrahydropyridopyrimidinone derivatives, their preparation and use
BG101126A (en) The use of muramylpeptide compounds
TR199901386T2 (en) �midazopiridazinler.
TR200200278T2 (en) Calcilitic compositions
ATE39694T1 (en) (PYRROL-1-YL)-PHENYL-DIHYDROPYRIDAZINONES, THEIR PREPARATION AND USE.
TR199901385T2 (en) Piperidin t�revleri.
NZ511997A (en) Isonipecotamides for the treatment of integrin-mediated disorders
MXPA02003731A (en) Novel fusidic acid derivatives.
NO880405D0 (en) PROCEDURE FOR THE PREPARATION OF 3-PHENYL-7H-TIAZOLO- / 3,2-B // 1,2,4 / -TIAZINE-7-ONER.